AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 186223 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4-cup equivalent)
Number of subjects: 18
Study 186223 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (4-cup equivalent)
Number of subjects: 18
Study 186223 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee and caffeine
Number of subjects: 18
Study 186223 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 18
Study 11231744 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine-zidovudine regimen
Number of subjects: 562
Study 11231744 — intervention group
Group type: COMPARATOR
Intervention: Indinavir-lamivudine-zidovudine regimen
Number of subjects: 562
Study 11231744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 562
Study 30475232 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous amisulpride
Number of subjects: 702
Study 30475232 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous amisulpride
Number of subjects: 702
Study 30475232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 29499855 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03463275 10 mg twice a day
Number of subjects: 0
Study 29499855 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03463275 20 mg twice a day
Number of subjects: 0
Study 29499855 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03463275 40 mg twice a day
Number of subjects: 0
Study 29499855 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03463275 60 mg twice a day
Number of subjects: 0
Study 29499855 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03463275 (various doses)
Number of subjects: 0
Study 29499855 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03463275
Number of subjects: 0
Study 27005893 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of vaginal micronized progesterone tablets (Group A)
Number of subjects: 300
Study 27005893 — intervention group
Group type: COMPARATOR
Intervention: 3 days of vaginal micronized progesterone (Group B)
Number of subjects: 300
Study 24650618 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete headway feedback
Number of subjects: 20
Study 24650618 — intervention group
Group type: COMPARATOR
Intervention: No headway feedback (Control)
Number of subjects: 20
Study 22278628 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (20-40 mg once daily by forced titration)
Number of subjects: 622
Study 22278628 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil (8-12 mg once daily by forced titration)
Number of subjects: 622
Study 20177043 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies incorporating patient perspective (exploring context, referring to mental health professional, offering alternative diagnosis)
Number of subjects: 199
Study 20177043 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical approaches (prescribing sleep aid or ordering diagnostic workup)
Number of subjects: 199
Study 20177043 — intervention group
Group type: EXPERIMENTAL
Intervention: Outright rejection of request
Number of subjects: 199
Study 18091641 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg/m2 G‐CSF bis in die subcutaneously (from day 0 to day 4) in addition to standard care
Number of subjects: 50
Study 18091641 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 15625266 — intervention group
Group type: EXPERIMENTAL
Intervention: StyletScope fibreoptic stylet (FOS)
Number of subjects: 193
Study 15625266 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal stylet (CMS)
Number of subjects: 193
Study 11892635 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural fentanyl (fentanyl group)
Number of subjects: 36
Study 11892635 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (saline group)
Number of subjects: 36
Study 9528717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution 200 mg/day for 14 days
Number of subjects: 179
Study 9528717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution 200 mg/day for 7 days
Number of subjects: 179
Study 9528717 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole tablets 100 mg/day for 14 days
Number of subjects: 179
Study 7629001 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole (MID) 300 mg/day for 1 week
Number of subjects: 13
Study 7629001 — intervention group
Group type: COMPARATOR
Intervention: Control group (asthmatics not taking beta 2‐agonists)
Number of subjects: 13
Study 2930674 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine 2 mg kg‐1 followed by an infusion of 2 mg kg‐1 h‐1
Number of subjects: 40
Study 2930674 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 40
Study 1013707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure intermittent compression (Phlebo‐Dynastat) to calves and thighs started on the day of operation and continued until patients were fully mobilized.
Number of subjects: 54
Study 1013707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 54
Study 1013707 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients treated with Phlebo‐Dynastat.
Number of subjects: 54
Study 30466547 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training
Number of subjects: 131
Study 30466547 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational skills
Number of subjects: 131
Study 30466547 — intervention group
Group type: EXPERIMENTAL
Intervention: RefCT and RefST
Number of subjects: 131
Study 30242745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day for 15 weeks)
Number of subjects: 539
Study 30242745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 30242745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 539
Study 27060101 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session self-management groups for PwD and their spouses
Number of subjects: 272
Study 27060101 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study 24669982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Facts table (NFt)
Number of subjects: 3029
Study 24669982 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light FOP system
Number of subjects: 3029
Study 24669982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Facts FOP system
Number of subjects: 3029
Study 24669982 — intervention group
Group type: COMPARATOR
Intervention: Summary indicator systems
Number of subjects: 3029
Study 21948599 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality‐based program (six sessions, 35‐40 minutes per session, three sessions per week)
Number of subjects: 16
Study 21948599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study 19910715 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 225
Study 19910715 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus lithium or valproate
Number of subjects: 225
Study 19910715 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine or olanzapine plus mood stabilizers
Number of subjects: 225
Study 19910715 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine or olanzapine plus lithium or valproate
Number of subjects: 225
Study 19910715 — intervention group
Group type: COMPARATOR
Intervention: Comparators (placebo, lithium, placebo plus lithium or valproate)
Number of subjects: 225
Study 17998546 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 7963
Study 17998546 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 7963
Study 15894149 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 115
Study 11561280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance
Number of subjects: 2
Study 11561280 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective high-risk screening
Number of subjects: 2
Study 11561280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management of small aneurysms
Number of subjects: 2
Study 11561280 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative intervention
Number of subjects: 2
Study 9389686 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg/kg/d subcutaneously)
Number of subjects: 521
Study 9389686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 8186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Number of subjects: 0
Study 8186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Megapulse
Number of subjects: 0
Study 8186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0
Study 8186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft laser
Number of subjects: 0
Study 8186034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3367371 — intervention group
Group type: EXPERIMENTAL
Intervention: External reward
Number of subjects: 153
Study 3367371 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reward
Number of subjects: 153
Study 3367371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 153
Study 29851439 — intervention group
Group type: EXPERIMENTAL
Intervention: EP phone call with mailed information
Number of subjects: 9093
Study 29851439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed information only
Number of subjects: 9093
Study 29851439 — intervention group
Group type: COMPARATOR
Intervention: No educational intervention
Number of subjects: 9093
Study 28402408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 80
Study 28402408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25644122 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 0.5, 1.0, or 2.0 g cefozopran hydrochloride
Number of subjects: 12
Study 25644122 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intravenous doses of 2.0 g cefozopran every 12 h for 4 days
Number of subjects: 12
Study 24219348 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 13072
Study 24219348 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin angiotensin system agents
Number of subjects: 13072
Study 24219348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers
Number of subjects: 13072
Study 24219348 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall BP medication management
Number of subjects: 13072
Study 21255253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII (25 IU kg(‐1) 3 × week)
Number of subjects: 45
Study 21255253 — intervention group
Group type: COMPARATOR
Intervention: Episodic therapy with ≥25 IU kg(‐1) every 12‐24 h until complete clinical bleeding resolution
Number of subjects: 45
Study 21255253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant factor VIII
Number of subjects: 45
Study 21255253 — intervention group
Group type: COMPARATOR
Intervention: Episodic therapy
Number of subjects: 45
Study 21255253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis started early (≤36 months)
Number of subjects: 45
Study 17396216 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (approximately 10 g/day over three months)
Number of subjects: 22
Study 17396216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 22
Study 17181437 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization in early life
Number of subjects: 0
Study 12925827 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasion and Carisolv gel
Number of subjects: 22
Study 12925827 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (local anaesthetic injection/drill)
Number of subjects: 22
Study 11037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (26.3 mM NaF)
Number of subjects: 11
Study 11037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate (20.0 mM)
Number of subjects: 11
Study 11037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride plus zinc acetate
Number of subjects: 11
Study 11037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine diacetate (2.2 mM)
Number of subjects: 11
Study 11037756 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus fluoride
Number of subjects: 11
Study 11037756 — intervention group
Group type: COMPARATOR
Intervention: Water (control; treatment A)
Number of subjects: 11
Study 9259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of nifedipine at 0.65 mg/h
Number of subjects: 60
Study 9259871 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of nifedipine at 1.25 mg/h
Number of subjects: 60
Study 9259871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 8075966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy/radiation arm
Number of subjects: 683
Study 8075966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation arm (HFX)
Number of subjects: 683
Study 8075966 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (STD)
Number of subjects: 683
Study 8075966 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky performance status (KPS) < 90 vs. > or = 90
Number of subjects: 683
Study 8075966 — intervention group
Group type: EXPERIMENTAL
Intervention: T-stage
Number of subjects: 683
Study 3316238 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Number of subjects: 0
Study 3316238 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation for six weeks in plaster
Number of subjects: 0
Study 31869437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 83576
Study 31869437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 83576
Study 31869437 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 83576
Study 31869437 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 83576
Study 29381791 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 262
Study 29381791 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy plus Meal Replacements (BT+MR)
Number of subjects: 262
Study 29381791 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Food Environment (HFE)
Number of subjects: 262
Study 27147900 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m²)
Number of subjects: 55
Study 27147900 — intervention group
Group type: COMPARATOR
Intervention: Three-weekly paclitaxel (175 mg/m²)
Number of subjects: 55
Study 24554232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (8 mg/d)
Number of subjects: 67
Study 24554232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 22938003 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper oxide-containing pillowcases (1% weight/weight)
Number of subjects: 61
Study 22938003 — intervention group
Group type: COMPARATOR
Intervention: Control pillowcases without copper
Number of subjects: 61
Study 20856164 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV vaccine (≥4 log10 plaque forming units) administered 1 month before or after hepatitis A control vaccine
Number of subjects: 300
Study 19035877 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg inhaled salbutamol via spacer device
Number of subjects: 20
Study 19035877 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized salbutamol
Number of subjects: 20
Study 19035877 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg inhaled salbutamol via spacer device (corrected for heart rate)
Number of subjects: 20
Study 19035877 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized salbutamol (corrected for heart rate)
Number of subjects: 20
Study 15663493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2000 mg) and Vitamin E (800 IU) daily for 7 days prior to cryotherapy
Number of subjects: 40
Study 15663493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12658400 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management of pain in chronic pancreatitis
Number of subjects: 0
Study 12658400 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative data on treatment options
Number of subjects: 0
Study 12658400 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological outcomes and quality-of-life issues
Number of subjects: 0
Study 9475828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0
Study 9475828 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 8108873 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 117
Study 8108873 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 117
Study 2697116 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine bid
Number of subjects: 20
Study 2697116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 788745 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 250 mug
Number of subjects: 7
Study 788745 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 500 mug
Number of subjects: 7
Study 788745 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 750 mug
Number of subjects: 7
Study 788745 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 1000 mug
Number of subjects: 7
Study 788745 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 7031979 — intervention group
Group type: COMPARATOR
Intervention: Cough alone
Number of subjects: 6
Study 7031979 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (including cough)
Number of subjects: 6
Study 31399142 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 45
Study 31399142 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 45
Study 31399142 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (regular meetings)
Number of subjects: 45
Study 29146120 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms at baseline and persistence
Number of subjects: 682
Study 29146120 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated screening for depressive symptoms
Number of subjects: 682
Study 26763498 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Treatment (WET) for PTSD
Number of subjects: 0
Study 26763498 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported arousal assessments
Number of subjects: 0
Study 27927405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive pads placed over the apex of scoliosis curves during Mehta casting
Number of subjects: 27
Study 27927405 — intervention group
Group type: COMPARATOR
Intervention: No adhesive pads (non-pad group) during Mehta casting
Number of subjects: 27
Study 21559793 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia (XE)
Number of subjects: 30
Study 21559793 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anesthesia (SEV)
Number of subjects: 30
Study 21559793 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 30
Study 18591366 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretically based rape prevention intervention
Number of subjects: 146
Study 18591366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study 16887123 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg extended-release niacin (n=20)
Number of subjects: 30
Study 16887123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 30
Study 15080372 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily indapamide (1 mg)
Number of subjects: 30
Study 15080372 — intervention group
Group type: EXPERIMENTAL
Intervention: Every other day indapamide (1 mg)
Number of subjects: 30
Study 15080372 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM with indapamide
Number of subjects: 30
Study 15080372 — intervention group
Group type: COMPARATOR
Intervention: ABPM without indapamide
Number of subjects: 30
Study 11841931 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 twice daily for 14 days every 3 weeks)
Number of subjects: 1200
Study 11841931 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/leucovorin (5-FU 425 mg/m2 plus leucovorin 20 mg/m2 days 1-5, every 4 weeks)
Number of subjects: 1200
Study 11841931 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 1200
Study 11841931 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and 5-FU/leucovorin
Number of subjects: 1200
Study 10565330 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutrition support
Number of subjects: 0
Study 10565330 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0
Study 10565330 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition
Number of subjects: 0
Study 7926082 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐agonist (GnRH‐a) treatment
Number of subjects: 6
Study 7926082 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 6
Study 7926082 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and weight-matched ovulatory women)
Number of subjects: 6
Study 2604961 — intervention group
Group type: EXPERIMENTAL
Intervention: Shofu GlasIonomer Base
Number of subjects: 3
Study 2604961 — intervention group
Group type: COMPARATOR
Intervention: Ketac‐Bond Aplicap
Number of subjects: 3
Study 2604961 — intervention group
Group type: COMPARATOR
Intervention: GC Dentin Cement
Number of subjects: 3
Study 1098808 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 45
Study 1098808 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45